At the time of writing, Nurix Therapeutics Inc [NRIX] stock is trading at $12.8, up 2.98%. An important factor to consider is whether the stock is rising or falling in short-term value. The NRIX shares have gain 3.98% over the last week, with a monthly amount glided 27.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on October 21, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $24. Previously, Leerink Partners started tracking the stock with Market Perform rating on March 17, 2025, and set its price target to $16. On December 10, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $35 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $35 on December 06, 2024. UBS initiated its recommendation with a Buy and recommended $35 as its price target on October 24, 2024. Jefferies started tracking with a Buy rating for this stock on October 11, 2024, and assigned it a price target of $41.
For the past year, the stock price of Nurix Therapeutics Inc fluctuated between $8.18 and $27.53. Currently, Wall Street analysts expect the stock to reach $26.75 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $12.8 at the most recent close of the market. An investor can expect a potential return of 108.98% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
According to Nurix Therapeutics Inc [NASDAQ:NRIX], the company’s sales were 83.69M for trailing twelve months, which represents an -37.29% plunge. Gross Profit Margin for this corporation currently stands at -1.63% with Operating Profit Margin at -3.19%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.54 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.28 points at the first support level, and at 11.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.26, and for the 2nd resistance point, it is at 13.73.
Ratios To Look Out For
It is important to note that Nurix Therapeutics Inc [NASDAQ:NRIX] has a current ratio of 5.35. On the other hand, the Quick Ratio is 5.35, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 15.50, the price to book ratio is 2.64.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on Nov 03 ’25 when 6284.0 shares were sold. Officer, JOHANNES VAN HOUTE completed a deal on Nov 03 ’25 to buy 6284.0 shares. Meanwhile, Chief Financial Officer van Houte Hans sold 3130.0 shares on Oct 30 ’25.
